Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b … Read more
Rein Therapeutics Inc (RNTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.077x
Based on the latest financial reports, Rein Therapeutics Inc (RNTX) has a cash flow conversion efficiency ratio of -0.077x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.55 Million) by net assets ($46.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rein Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Rein Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rein Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rein Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FERMENTALG EO -04
F:1F6
|
N/A |
|
Van Dien Fused Magnesium Phosphate Fertilizer JSC
VN:VAF
|
N/A |
|
Mural Oncology plc
NASDAQ:MURA
|
-0.335x |
|
Shapir Engineering Industry
TA:SPEN
|
-0.053x |
|
Capital Small Finance Bank Limited
NSE:CAPITALSFB
|
0.052x |
|
09women Co. Ltd.
KQ:366030
|
0.011x |
|
Joong Ang Enervis Co. Ltd
KQ:000440
|
0.009x |
|
Ferrari Group PLC
AS:FERGR
|
0.078x |
Annual Cash Flow Conversion Efficiency for Rein Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Rein Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $54.39 Million | $-22.29 Million | -0.410x | +85.75% |
| 2023-12-31 | $6.89 Million | $-19.81 Million | -2.876x | -115.41% |
| 2022-12-31 | $18.62 Million | $-24.86 Million | -1.335x | -146.78% |
| 2021-12-31 | $43.90 Million | $-23.75 Million | -0.541x | +67.86% |
| 2020-12-31 | $12.16 Million | $-20.48 Million | -1.684x | -2.06% |
| 2019-12-31 | $16.05 Million | $-26.47 Million | -1.650x | -15.78% |
| 2018-12-31 | $19.60 Million | $-27.93 Million | -1.425x | -231.70% |
| 2017-12-31 | $47.80 Million | $-20.53 Million | -0.430x | -419.87% |
| 2016-12-31 | $-111.81 Million | $-15.01 Million | 0.134x | +8.16% |
| 2015-12-31 | $-94.32 Million | $-11.71 Million | 0.124x | -- |